Evidence map›Paper›PMID 39739600›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Novel Naphthyridones Targeting Pannexin 1 for Colitis Management.

Wen-Yun Hsueh, Yi-Ling Wu, Meng-Tzu Weng, Shin-Yun Liu, Jascinta P Santavanond, Yi-Chung Liu, Ching-I Lin, Cheng-Nong Lai, Yi-Ru Lu, Jing Yin Hsu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Novel Naphthyridones Targeting Pannexin 1 for Colitis Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Wen-Yun HsuehDepartment of Chemistry, National Tsing Hua University, Hsinchu, 300044, Taiwan.
Yi-Ling WuInstitute of Biotechnology, National Tsing Hua University, Hsinchu, 300044, Taiwan.
Meng-Tzu WengDepartment of Internal Medicine, National Taiwan University Hospital, Taipei City, 100229, Taiwan.
Shin-Yun LiuDepartment of Internal Medicine, National Taiwan University Hospital, Taipei City, 100229, Taiwan.
Jascinta P SantavanondDepartment of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia.
Yi-Chung LiuInstitute of Population Health Sciences, National Health Research Institutes, Miaoli County, 350401, Taiwan.
Ching-I LinDepartment of Internal Medicine, National Taiwan University Hospital, Taipei City, 100229, Taiwan.
Cheng-Nong LaiInstitute of Biotechnology, National Tsing Hua University, Hsinchu, 300044, Taiwan.
Yi-Ru LuInstitute of Biotechnology, National Tsing Hua University, Hsinchu, 300044, Taiwan.
Jing Yin HsuInstitute of Biotechnology, National Tsing Hua University, Hsinchu, 300044, Taiwan.
Hong-Yu GaoInstitute of Biotechnology, National Tsing Hua University, Hsinchu, 300044, Taiwan.
Jinq-Chyi LeeInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 350401, Taiwan.
Shu-Chen WeiDepartment of Internal Medicine, National Taiwan University Hospital, Taipei City, 100229, Taiwan.
Ping-Chiang LyuInstitute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu, 300044, Taiwan.
Ivan K H PoonDepartment of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia.
Hsing-Pang HsiehDepartment of Chemistry, National Tsing Hua University, Hsinchu, 300044, Taiwan.ORCID https://orcid.org/0000-0002-1332-005X
Yu-Hsin ChiuInstitute of Biotechnology, National Tsing Hua University, Hsinchu, 300044, Taiwan.ORCID https://orcid.org/0000-0002-4730-8104

Funding

National Health Research Institutes BP-113-SP-07 to J.-C.LNational Science and Technology Council 113-2113-M-400-001- to H.-P.HNational Science and Technology Council 113-2314-B-002-237-MY2 to M.-T.W. and Y.-H.CNational Science and Technology Council 113-2628-B-007-002-MY3 to Y.-H.C and H.-P.HNational Taiwan University Hospital 113-BIH044 to M.-T.WNational Tsing Hua University through the Ministry of Education's Higher Education Sprout Project 113Q2525E1 to Y.-H.C.
6 · The paper itself

Abstract

Pannexin 1 (PANX1) forms cell-surface channels capable of releasing signaling metabolites for diverse patho-physiological processes. While inhibiting dysregulated PANX1 has been proposed as a therapeutic strategy for many pathological conditions, including inflammatory bowel disease (IBD), low efficacy, or poor specificity of classical PANX1 inhibitors introduces uncertainty for their applications in basic and translational research. Here, hit-to-lead optimization is performed and a naphthyridone, compound 12, is identified as a new PANX1 inhibitor with an IC

Indexed as

ColitisConnexinsNerve Tissue ProteinsAnimalsDisease Models, AnimalHumansInflammatory Bowel DiseasesMiceMice, Inbred C57BLMolecular Docking SimulationStructure-Activity RelationshipConnexinsNerve Tissue ProteinsPANX1 protein, humanPanx1 protein, mousecolitisinflammatory bowel diseaseLRRC8naphthyridonePannexinstructure–activity relationshiptrovafloxacin

Identifiers

PMID39739600
PMCPMC11831487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.